MedTrace Logo

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

NCT06017609 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 314

Last updated 2026-05-22

No results posted yet for this study

Summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

Conditions

Interventions

DRUG

JTT-861 Capsules

Active drug capsules containing JTT-861

DRUG

Placebo Capsules

Placebo capsules matching in appearance to the active drug capsules

Sponsors & Collaborators

  • ICON Clinical Research

    collaborator INDUSTRY

  • Akros Pharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-20
Primary Completion
2026-05-18
Completion
2026-05-18
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Czechia
  • Poland
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06017609 on ClinicalTrials.gov